ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3].

BACKGROUND & OBJECTIVE: Recent studies have shown that overexpression of Fas associated phosphatase-1 (FAP-1) can been detected in human ovarian cancer cell line SKOV3, suggesting that this overexpression may play an important role in the tumorigenesis and drug resistance of ovarian cancer. This study was designed to explore the effects of fas associated phosphatase-1 antisense oligonucleotide (FAP-1 ASODN) combined with carboplatin on the apoptosis of ovarian cancer cell SKOV3.

METHODS: Antisense oligonucleotide technique was used to transfect FAP-1 ASODN into SKOV3 cells. The expression levels of FAP-1 mRNA of SKOV3 cells with or without FAP-1 ASODN transfection were determined by reverse transcription- polymerase chain reaction (RT-PCR). The cell cycle and apoptotic rate were analyzed by flow cytometry (FCM). The growth and proliferation of SKOV3 cells were observed by MTT assay.

RESULTS: After transfected FAP-1 ASODN for 24 hours, the expression of FAP-1 mRNA in SKOV3 cells was obviously reduced compared with those of the control and FAP-1 SODN transfection groups. When induced apoptosis with 40 microg/ml carboplatin for 24-72 hours, FCM results showed the apoptotic rate of "carboplatin+FAP-1 ASODN" group was higher than those of "carboplatin" group and "ASODN" group (P< 0.05), and the cell cycle was blocked in G1 phase. MTT results showed the cell inhibitory rate of "carboplatin+FAP-1 ASODN" group was 1.5-2 times those of "carboplatin" group and "ASODN" group (P< 0.05); but no significant difference was found between "carboplatin" group and "carboplatin+FAP-1 SODN" group (P >0.05).

CONCLUSION: FAP-1 ASODN transfection can suppress the expression of FAP-1 gene in SKOV3 cells and enhance the cell sensitivity to apoptosis induced by carboplatin, which implies that FAP-1 ASODN may reverse the drug resistance in ovarian cancer.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app